Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
domenica, ottobre 25
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Krystal Biotech Inc
KRYS
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$311.50
-8.63
-2.7%
Ult. Agg.: Oct 23, 4:27 PM
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Utili:
I risultati di Q3 2026 tra 8 giorni da adesso in lun nov 2nd, prima dell'apertura del mercato
Krystal Biotech Financials
Krystal Biotech (KRYS) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Krystal Biotech Q2 EPS $1.79 Beats $1.66 Estimate, Sales $119.222M Miss $121.061M Estimate
Krystal Biotech (NASDAQ:KRYS) reported quarterly earnings of $1.79 per share which beat the analyst consensus estimate of $1.66 by 7.83 percent. This is a 38.76 percent increase over earnings of $1.29 per share from the
Benzinga Newsdesk
Krystal Biotech Analysts Boost Their Forecasts Following Upbeat Q1 Results
Krystal Biotech (KRYS) reported strong Q1 earnings, beating analyst estimates and with potential for future growth. Shares fell 1% on Tuesday.
Avi Kapoor
Earnings Scheduled For May 4, 2026
Benzinga Insights
PRO
Krystal Biotech Q1 EPS $1.83 Beats $1.39 Estimate, Sales $116.357M Beat $112.132M Estimate
Krystal Biotech (NASDAQ:KRYS) reported quarterly earnings of $1.83 per share which beat the analyst consensus estimate of $1.39 by 31.65 percent. This is a 52.5 percent increase over earnings of $1.20 per share from the
Benzinga Newsdesk
Krystal Biotech: Q4 Earnings Insights
Benzinga Insights
PRO
Krystal Biotech Q4 EPS $1.70 Beats $1.39 Estimate, Sales $107.105M Beat $105.338M Estimate
Krystal Biotech (NASDAQ:KRYS) reported quarterly earnings of $1.70 per share which beat the analyst consensus estimate of $1.39 by 22.21 percent. This is a 11.84 percent increase over earnings of $1.52 per share from the
Benzinga Newsdesk
